Dermatomyositis associated with omalizumab therapy for severe asthma: a case report
Abstract Background Omalizumab is a humanized monoclonal antibody widely used for treatment of persistent allergic asthma and antihistamine-refractory chronic urticaria. Immediate adverse events to omalizumab are well characterized. Delayed anaphylactoid and serum sickness-like reactions have also b...
Main Authors: | Samira Jeimy, Pari Basharat, Fiona Lovegrove |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2019-01-01
|
Series: | Allergy, Asthma & Clinical Immunology |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s13223-019-0319-4 |
Similar Items
-
Real-World Safety and Effectiveness of Omalizumab in Moderate to Severe Allergic Asthma Patients in China: A Post-Authorization Study
by: Su N, et al.
Published: (2023-06-01) -
Benefits of omalizumab on anxiety and depression in patients with severe asthma
by: Fatih Uzer, et al.
Published: (2018-05-01) -
A review of omalizumab for the management of severe asthma
by: Lin CH, et al.
Published: (2016-07-01) -
Omalizumab: An Optimal Choice for Patients with Severe Allergic Asthma
by: Serafeim Chrysovalantis Kotoulas, et al.
Published: (2022-01-01) -
Immunological Aspects Related to Viral Infections in Severe Asthma and the Role of Omalizumab
by: Francesco Menzella, et al.
Published: (2021-03-01)